Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Double-Blind Placebo-Controlled Phase 1, Safety and Immunogenicity Study of Two Dosages of Intranasal Norwalk Virus-like Particle Vaccine ( Norwalk VLP Antigen, MPL®, Chitosan, Mannitol, and Sucrose) Compared to Adjuvant/Excipients (MPL®, Chitosan, Mannitol, and Sucrose) and to Placebo (Empty Device

NCT00806962 is registered in ClinicalTrials.gov with LigoCyte Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00806962
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00806962 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Double-Blind Placebo-Controlled Phase 1, Safety and Immunogenicity Study of Two Dosages of Intranasal Norwalk Virus-like Particle Vaccine ( Norwalk VLP Antigen, MPL®, Chitosan, Mannitol, and Sucrose) Compared to Adjuvant/Excipients (MPL®, Chitosan, Mannitol, and Sucrose) and to Placebo (Empty Device
Lead sponsor
LigoCyte Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2008
Completion date
October 31, 2009
Enrollment
61 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

norovirus